Danish drugmaker Novo Nordisk is preparing to launch its blockbuster diabetes drug Ozempic in India later this month, according to three sources familiar with the development. With India emerging as a global hotspot for type 2 diabetes and obesity, the company aims to strengthen its position in one of the world’s fastest-growing markets for weight-loss and diabetes therapies.
India Becomes a Key Market for Metabolic Drugs
India now has the second-highest number of people living with type 2 diabetes after China. Rising obesity rates have further intensified demand for advanced metabolic medications. Analysts estimate that the global weight-loss drug market could reach $150 billion annually by 2030, making India a crucial destination for pharmaceutical companies.
Ozempic’s Global Success Drives India Strategy
Ozempic, approved by the U.S. FDA in 2017 as a once-weekly injectable for type 2 diabetes, has become a worldwide bestseller. Its off-label use for weight loss—due to its appetite-suppressing effects—has significantly boosted demand. Novo’s other semaglutide-based drug, Wegovy, is specifically approved for weight reduction.
One source noted, “Novo wants Ozempic in the market before generics introduce cheaper alternatives,” indicating that the launch could take place within the next three to four weeks.
Company Confirms Plans, Focuses on Competitive Pricing
Novo Nordisk received Indian regulatory approval in September to import and sell Ozempic. While the company has not confirmed an exact launch date or pricing, it emphasised its commitment to affordability.
“Novo understands that India is a price-sensitive market, and we are working hard to price Ozempic competitively,” said Vikrant Shrotriya, Managing Director, Novo Nordisk India.
He added that Ozempic’s arrival will complete the company’s semaglutide portfolio for diabetes and obesity care in India.
Facing Strong Competition From Eli Lilly
As reported by Reuters, the Indian market for GLP-1 agonists is rapidly evolving. Eli Lilly’s Mounjaro, approved for diabetes and weight loss, has already become India’s top-selling drug by value as of October. Pharmarack data shows Lilly sold 262,000 doses of Mounjaro in October, compared with 26,000 doses of Wegovy, which launched in June.
In response, Novo Nordisk cut Wegovy’s price in India by up to 37% ahead of the March 2026 patent expiry for semaglutide, which will open the floodgates for generics.
Indian Generics Prepare to Enter the Market
Several Indian pharmaceutical companies—including Sun Pharma, Cipla, Dr. Reddy’s, and Lupin—are already developing their own versions of semaglutide. These generic alternatives are expected to reshape the weight-loss and diabetes market once patents expire.
Novo Leverages Its Diabetes Leadership in India
Analyst Vishal Manchanda of Systematix Institutional Equities said Novo already enjoys a strong presence in India’s diabetes sector, supported by its oral semaglutide brand Rybelsus and other products. This foothold will help the company aggressively promote Ozempic.
He added, “Ozempic could also be prescribed for conditions such as infertility, sleep apnea, and weight management, depending on clinical evaluation.”
GLP-1 Drugs Reshape Treatment Paradigms
Ozempic, Wegovy, and Mounjaro belong to the GLP-1 agonist class of medications. Originally developed for diabetes, they mimic a naturally occurring hormone that slows digestion and enhances satiety. This makes them highly effective for both blood sugar control and weight reduction.